Get the Stockscreener App
0.96
3.31%
-0.0329
Renovorx Inc stock is traded at $0.96, with a volume of 177.68K.
It is down -3.31% in the last 24 hours and down -4.00% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.9929
Open:
$0.98
24h Volume:
177.68K
Relative Volume:
0.35
Market Cap:
$35.18M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.6842
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
+1.99%
1M Performance:
-4.00%
6M Performance:
-29.41%
1Y Performance:
-27.27%
1-Day Range:
$0.9469
$0.9998
1-Week Range:
$0.9201
$1.00
52-Week Range:
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.96 | 36.39M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO GI 2026 on Innovative Targeted Therapy for Pancreatic Cancer - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 - Stock Titan
Transcript : RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, Dec-09-2025 through Dec-10-2025 - marketscreener.com
RNXT: Six-month survival benefit and strong early revenue position the company for growth in 2026 - TradingView — Track All Markets
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Investing News Network
Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx (RNXT) Stock Analysis Report | Financials & Insights - Benzinga
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Investing News Network
RenovoRx CEO to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) CEO to detail RenovoCath updates at iAccess Alpha - Stock Titan
RenovoRx files $50M mixed securities shelf - MSN
Big Money Moves: Is RenovoRx Inc. stock attractive for growth ETFsMarket Trend Review & Safe Entry Zone Tips - BỘ NỘI VỤ
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
[Form 4] RenovoRx, Inc. Insider Trading Activity - Stock Titan
RenovoRx CMO Ramtin Agah Acquires 22,000 Shares - TradingView
Cipla Limited (CIPLA) Gets Regulatory ApprovalFinancial Sector Performance & Stay One Step Ahead of Risk Events - earlytimes.in
Is RenovoRx Inc. stock positioned for long term growthRisk Management & Reliable Volume Spike Trade Alerts - newser.com
Is RenovoRx Inc. stock a top pick in earnings seasonWeekly Profit Report & Community Driven Trade Alerts - newser.com
RenovoRx Expands Reach with RenovoCath Approval - MSN
Is RenovoRx Inc. stock dividend yield sustainablePortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-19 17:29:20 - newser.com
Tick level data insight on RenovoRx Inc. volatility2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - Investing News Network
RenovoRx CEO Shaun Bagai to Present at Alliance Global Partners Virtual Showcase on Oncology Innovations - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Share RenovoCath, $900K YTD Revenue at AGP Showcase - Stock Titan
What drives RenovoRx Inc stock pricePrice Gap Trading Strategies & Go Beyond the Headlines With Analyst Picks - earlytimes.in
Does RenovoRx Inc. fit your quant trading modelJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
RenovoRx : Corporate Overview - MarketScreener
Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx - TipRanks
Can RenovoRx Inc. stock deliver consistent earnings growthJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
RenovoRx launches public stock offering - MSN
Is RenovoRx Inc. stock supported by innovation pipelineBull Run & Free Safe Entry Trade Signal Reports - newser.com
Can machine learning forecast RenovoRx Inc. recoveryJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
RenovoRx Earnings Call: Positive Momentum and Strategic Growth - MSN
RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating - TipRanks
RenovoRx price target lowered to $3 from $3.50 at Alliance Global - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX) - The Globe and Mail
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):